Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | Aplastic Anemia & MDS International Foundation
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

Clinical Trial: NCT00167219

For more details on this clinical trial, including contact information, please see this trial’s listing on

The investigators hypothesize that long-term disease-free survival (DFS) in patients with JMML can be achieved with a treatment of busulfan (BU), cyclophosphamide (CY) and melphalan (L-PAM) followed by hematopoietic cell transplantation (HCT).

Study Date: 
Wed, 12/01/1999 to Tue, 12/01/2020
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Procedure: Stem Cell Transplant As part of the stem-cell transplant process, patients receive high doses of chemotherapy to treat their underlying disease, such as cancer. This treatment also kills the healthy stem cells already in the marrow. The transplanted cells from a donor replace the patient's bone marrow and allow the blood counts to recover. Subjects will receive BUSULFAN via the central venous line, six times a day for four days, CYCLOPHOSPHAMIDE via the central venous line once a day for two days, and MELPHALAN via the central venous line for one day.On the day of transplantation, cells from the donor will arrive to the bone marrow transplant unit and be transfused via venous line. Other Name: Bone marrow transplantation